Zealand Pharma A/S. - ADR logo

ZEAL

Zealand Pharma A/S. - ADR

$19.43

Earnings Summary

Revenue
$15.08Mn
Net Profits
$-222.85Mn
Net Profit Margins
-1478.05%

Highlights

Revenue:

Zealand Pharma A/S. - ADR’s revenue fell -68.47% since last year same period to $15.08Mn in the Q1 2022. On a quarterly growth basis, Zealand Pharma A/S. - ADR has generated -72.09% fall in its revenue since last 3-months.

Net Profits:

Zealand Pharma A/S. - ADR’s net profit jumped 7.99% since last year same period to $-222.85Mn in the Q1 2022. On a quarterly growth basis, Zealand Pharma A/S. - ADR has generated 20.49% jump in its net profits since last 3-months.

Net Profit Margins:

Zealand Pharma A/S. - ADR’s net profit margin fell -191.84% since last year same period to -1478.05% in the Q1 2022. On a quarterly growth basis, Zealand Pharma A/S. - ADR has generated -184.86% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Zealand Pharma A/S. - ADR post its latest quarter earnings

EPS Estimate Current Quarter
-6.61
EPS Estimate Current Year
-6.61

Highlights

EPS Estimate Current Quarter:

Zealand Pharma A/S. - ADR’s earning per share (EPS) estimates for the current quarter stand at -6.61 - a -3.44% fall from last quarter’s estimates.

EPS Estimate Current Year:

Zealand Pharma A/S. - ADR’s earning per share (EPS) estimates for the current year stand at -6.61.

Key Ratios

Key ratios of the Zealand Pharma A/S. - ADR post its Q1 2022 earnings

Earning Per Share (EPS)
-5.16
Return on Assets (ROA)
-0.34
Return on Equity (ROE)
-0.94
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Zealand Pharma A/S. - ADR’s earning per share (EPS) jumped 10.73% since last year same period to -5.16 in the Q1 2022. This indicates that the Zealand Pharma A/S. - ADR has generated 10.73% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Zealand Pharma A/S. - ADR’s return on assets (ROA) stands at -0.34.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Zealand Pharma A/S. - ADR’s return on equity (ROE) stands at -0.94.

Dividend Per Share (DPS):

Zealand Pharma A/S. - ADR declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-03-31
-6.61
-5.16
21.94%

Company Information

Organisation
Zealand Pharma A/S. - ADR
Headquarters
Sydmarken 11, Soeborg, Denmark
Employees
329
Industry
Health Technology
CEO
Emmanuel Dulac